<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ian Chan | Deep-Tech & Financial Analysis</title>
    <style>
        /* --- Global Styles & Variables --- */
        :root {
            --bg-color: #1a1a1a;
            --text-color: #e0e0e0;
            --primary-color: #00aaff;
            --secondary-color: #2c2c2c;
            --header-font: 'Helvetica Neue', Helvetica, Arial, sans-serif;
            --body-font: 'Georgia', serif;
        }

        html {
            scroll-behavior: smooth;
        }

        body {
            background-color: var(--bg-color);
            color: var(--text-color);
            font-family: var(--body-font);
            margin: 0;
            line-height: 1.6;
            font-size: 18px;
        }

       .container {
            max-width: 900px;
            margin: 0 auto;
            padding: 20px;
        }

        /* --- Header & Navigation --- */
        header {
            background-color: rgba(26, 26, 26, 0.9);
            padding: 1rem 0;
            position: fixed;
            width: 100%;
            top: 0;
            z-index: 1000;
            backdrop-filter: blur(10px);
            border-bottom: 1px solid var(--secondary-color);
        }

        nav {
            display: flex;
            justify-content: space-between;
            align-items: center;
            max-width: 1200px;
            margin: 0 auto;
            padding: 0 20px;
        }

        nav.logo {
            font-family: var(--header-font);
            font-size: 1.5rem;
            font-weight: bold;
            color: var(--text-color);
            text-decoration: none;
        }

        nav ul {
            list-style: none;
            margin: 0;
            padding: 0;
            display: flex;
        }

        nav ul li {
            margin-left: 25px;
        }

        nav ul li a {
            color: var(--text-color);
            text-decoration: none;
            font-family: var(--header-font);
            font-weight: 500;
            transition: color 0.3s ease;
        }

        nav ul li a:hover {
            color: var(--primary-color);
        }

        /* --- Hero Section --- */
       .hero {
            padding-top: 150px;
            padding-bottom: 100px;
            text-align: center;
        }

       .hero h1 {
            font-family: var(--header-font);
            font-size: 3.5rem;
            margin-bottom: 10px;
        }

       .hero h2 {
            font-family: var(--header-font);
            font-size: 1.5rem;
            color: var(--primary-color);
            font-weight: 400;
            margin-bottom: 20px;
        }

       .hero p {
            max-width: 600px;
            margin: 0 auto 40px auto;
            font-size: 1.1rem;
        }

        /* --- Project Cards Section --- */
       .project-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 30px;
            margin-top: 50px;
        }

       .project-card {
            background-color: var(--secondary-color);
            padding: 30px;
            border-radius: 8px;
            text-decoration: none;
            color: var(--text-color);
            transition: transform 0.3s ease, box-shadow 0.3s ease;
            border: 1px solid #444;
        }

       .project-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 20px rgba(0, 0, 0, 0.2);
        }

       .project-card h3 {
            font-family: var(--header-font);
            color: var(--primary-color);
            margin-top: 0;
        }

        /* --- Project Detail Pages --- */
       .project-page {
            padding-top: 100px;
            border-bottom: 1px solid var(--secondary-color);
            padding-bottom: 50px;
        }

       .project-page h2 {
            font-family: var(--header-font);
            font-size: 2.8rem;
            color: var(--primary-color);
            border-bottom: 2px solid var(--primary-color);
            padding-bottom: 10px;
            margin-bottom: 30px;
        }

       .project-page h3 {
            font-family: var(--header-font);
            font-size: 1.6rem;
            color: #cccccc;
            margin-top: 40px;
            border-left: 3px solid var(--primary-color);
            padding-left: 15px;
        }
        
       .project-page ul {
            list-style-type: none;
            padding-left: 0;
        }

       .project-page li {
            background: url('data:image/svg+xml;utf8,<svg xmlns="http://www.w3.org/2000/svg" width="18" height="18" viewBox="0 0 24 24" fill="none" stroke="%2300aaff" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M22 11.08V12a10 10 0 1 1-5.93-9.14"></path><polyline points="22 4 12 14.01 9 11.01"></polyline></svg>') no-repeat left center;
            padding-left: 30px;
            margin-bottom: 15px;
        }

        /* --- Footer --- */
        footer {
            text-align: center;
            padding: 40px 20px;
            margin-top: 50px;
            border-top: 1px solid var(--secondary-color);
        }

       .footer-links a {
            color: var(--text-color);
            text-decoration: none;
            margin: 0 15px;
            font-family: var(--header-font);
            transition: color 0.3s ease;
        }

       .footer-links a:hover {
            color: var(--primary-color);
        }

        /* --- Responsive Design --- */
        @media (max-width: 768px) {
           .hero h1 {
                font-size: 2.5rem;
            }
           .project-grid {
                grid-template-columns: 1fr;
            }
            nav ul {
                display: none; /* Simple responsive solution for a small site */
            }
        }

    </style>
</head>
<body>

    <header>
        <nav>
            <a href="#home" class="logo">IAN CHAN</a>
            <ul>
                <li><a href="#project1">Case Study 1</a></li>
                <li><a href="#project2">Case Study 2</a></li>
            </ul>
        </nav>
    </header>

    <main>
        <div id="home" class="hero container">
            <h1>Ian Chan</h1>
            <h2>Deep-Tech Analyst & Biomedical Engineer</h2>
            <p>A biomedical engineer with a passion for transforming technical innovations into commercially viable solutions. Below are investment case studies on two key projects.</p>
            <div class="project-grid">
                <a href="#project1" class="project-card">
                    <h3>Case Study 01</h3>
                    <p>Wearable Pulse Oximeter: An analysis of a patient-centric health monitor with a distinct competitive edge in the remote patient monitoring market.</p>
                </a>
                <a href="#project2" class="project-card">
                    <h3>Case Study 02</h3>
                    <p>Objective Pain Quantification: An evaluation of a first-in-class device poised to disrupt the clinical trial market for pain therapeutics.</p>
                </a>
            </div>
        </div>

        <div class="container">
            <section id="project1" class="project-page">
                <h2>Case Study: Wearable Pulse Oximeter</h2>
                
                <h3>Executive Summary</h3>
                <p>This project involved the end-to-end development of a patient-centric wearable pulse oximeter, from concept to a functional, award-winning prototype. The device targets the rapidly expanding remote patient monitoring market, offering a superior value proposition through enhanced accuracy and extended operational life. The proposed B2B commercialization strategy positions the device as a high-value asset for hospitals and telehealth providers seeking to improve post-operative patient outcomes and reduce readmission rates.</p>

                <h3>Technical Innovation (The Alpha)</h3>
                <ul>
                    <li>Developed a proprietary signal processing algorithm (FFT in MATLAB) that filters motion artifacts, achieving 95% accuracy and improving data reliability by over 15% compared to existing consumer-grade devices.</li>
                    <li>Engineered a low-power, flexible sensor array enabling continuous, uninterrupted monitoring for over 72 hours, a significant improvement on the 24-48 hour lifespan of current market alternatives.</li>
                    <li>Designed as a fully integrated system, combining hardware with a robust business case, demonstrating a holistic understanding of the product lifecycle from scientific validation to market entry.</li>
                </ul>

                <h3>Market Analysis</h3>
                <ul>
                    <li>Targets the global remote patient monitoring (RPM) market, a sector projected to grow significantly as healthcare systems shift towards decentralized care.</li>
                    <li>Initial addressable market focuses on post-operative recovery patients, a critical segment where continuous, accurate monitoring can directly impact clinical outcomes and reduce costly hospital readmissions.</li>
                    <li>The market is currently fragmented with devices that lack either clinical-grade accuracy or the battery life required for multi-day monitoring, presenting a clear opportunity for a superior product.</li>
                </ul>

                <h3>Commercial Viability</h3>
                <ul>
                    <li>Proposed a B2B sales model targeting hospitals and telehealth service providers, offering the device as part of a comprehensive patient monitoring package.</li>
                    <li>The Unique Selling Proposition (USP) is a combination of superior accuracy (95%) and extended battery life (72+ hours), creating a strong competitive moat against incumbents.</li>
                    <li>The device's ability to provide reliable, long-term data reduces the need for frequent nurse check-ins and enables early detection of complications, offering a clear ROI for healthcare providers through improved efficiency and patient care.</li>
                </ul>
            </section>

            <section id="project2" class="project-page">
                <h2>Case Study: Objective Pain Quantification Device</h2>

                <h3>Executive Summary</h3>
                <p>This project developed a predictive pain index by applying machine learning models to physiological data, creating a first-mover advantage in a market reliant on subjective, qualitative pain scales. The device is a non-invasive tool designed to provide objective, real-time pain data, targeting the high-value clinical trial market for new analgesic drugs. The proposed Data-as-a-Service (DaaS) model offers a scalable, high-margin revenue stream by providing pharmaceutical companies and CROs with the reliable, quantifiable data needed to accelerate drug development and secure regulatory approval.</p>

                <h3>Technical Innovation (The Alpha)</h3>
                <ul>
                    <li>Created a novel composite pain biomarker by applying machine learning and regression models (Python, Scikit-learn) to complex physiological data streams, including Galvanic Skin Response (GSR) and Electromyography (EMG).</li>
                    <li>Engineered a non-invasive wearable sensor that provides real-time, quantifiable pain data to a clinician's dashboard, replacing the antiquated 1-10 subjective pain scale with objective metrics.</li>
                    <li>The predictive index demonstrates advanced data modeling capabilities, translating noisy biological signals into a clear, actionable pain score.</li>
                </ul>

                <h3>Market Analysis</h3>
                <ul>
                    <li>Addresses a critical unmet need within the multi-billion dollar clinical drug trial market for pain therapeutics, where objective efficacy data is paramount for FDA and EMA approval.</li>
                    <li>The primary target market consists of pharmaceutical companies and Contract Research Organizations (CROs) that stand to save millions in trial costs and time with more reliable endpoint data.</li>
                    <li>The current market standard (patient-reported pain scores) is notoriously unreliable and subject to placebo effects, creating significant risk and cost in drug development. This device directly mitigates that risk.</li>
                </ul>

                <h3>Commercial Viability</h3>
                <ul>
                    <li>Positioned for a high-margin Data-as-a-Service (DaaS) or licensing model, providing trial sponsors with access to the device and its data analytics platform on a per-patient or per-trial basis.</li>
                    <li>Establishes a strong competitive moat as a first-mover in a niche with no existing objective measurement tools, creating high switching costs for clients who integrate the data into their trial protocols.</li>
                    <li>The ability to provide objective proof of a drug's efficacy can de-risk the development process, accelerate time-to-market, and strengthen a new drug's value proposition to regulators and insurers, representing immense value to clients.</li>
                </ul>
            </section>
        </div>
    </main>

    <footer>
        <div class="container footer-links">
            <a href="mailto:ianchanhy@gmail.com">Email</a> &bull;
            <a href="https://www.linkedin.com/in/ian-chan-6266b5239" target="_blank">LinkedIn</a> &bull;
            <a href="" target="_blank">Download CV</a>
        </div>
    </footer>

</body>
</html>
